SCHEMBL7556493

SCHEMBL7556493

COc1ccc(NC(=O)Nc2ccc3[nH]cc(C=C4SC(=O)N(Cc5ccc(Cl)c(Cl)c5)C4=O)c3c2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.42
▸ ALOX5 P09917 1/20 0.41
▸ MEN1 O00255 6/20 0.40
▸ KMT2A Q03164 6/20 0.40
▸ MAPT P10636 5/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MCL1 Q07820 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ DNMT1 P26358 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ DUSP3 P51452 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ PTPN1 P18031 1/20 0.38
▸ ACP1 P24666 1/20 0.38
▸ NTRK1 P04629 1/20 0.38
▸ NTRK2 Q16620 1/20 0.38
▸ PIK3CA P42336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7557088 0.88 SLC2A1 (0.45) PPARGALOX5MEN1KMT2AMAPT
SCHEMBL7554795 0.85 ACHE (0.47) PPARGALOX5MEN1KMT2AMAPT
SCHEMBL7557692 0.81 ENPP2 (0.46) PPARGMEN1KMT2AMAPTKDM4E
SCHEMBL7553259 0.80 PTPN1 (0.45) MEN1KMT2AMAPTPTPN1ACP1
SCHEMBL7556297 0.79 SLC2A1 (0.44) PPARGMEN1KMT2AMAPTDUSP3
SCHEMBL7556649 0.77 MAOB (0.39) PPARGALOX5MEN1KMT2AALDH1A1
SCHEMBL7556489 0.75 GSK3B (0.47) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL7556496 0.75 GSK3B (0.47) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL7559213 0.75 PTPN1 (0.40) PPARGALOX5MEN1KMT2APTPN1
SCHEMBL5470542 0.74 PTPN1 (0.48) PPARGMEN1KMT2APTPN1ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020115700-A1 Substituted indole compounds and methods of their use CHIN ALLISON C (US) 2002-08-22 — — US disclosed
US-6372742-B1 TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS GERON CORPORATION 2002-04-16 — — US disclosed
EP-1109808-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER Geron Corporation (US) 2001-06-27 — — EP disclosed
WO-2001002394-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER GERON CORPORATION (US) 2001-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115700-A1 Substituted indole compounds and methods of their use TERT, INMT, POT1 PPARG 3269/4885ALOX5 1916/4885MEN1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback